Working… Menu
Trial record 1 of 1 for:    NCT04409262
Previous Study | Return to List | Next Study

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04409262
Recruitment Status : Completed
First Posted : June 1, 2020
Last Update Posted : March 11, 2021
Gilead Sciences
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : February 1, 2021
Actual Study Completion Date : March 8, 2021